RegenXBio (RGNX) has shared an update.
REGENXBIO Inc. has awarded substantial restricted stock units (RSUs) to two of its top executives to ensure leadership stability amidst a CEO transition. Stephen Pakola, M.D., and Olivier Danos, Ph.D., received nearly 59,000 RSUs each, which will gradually vest over two years, contingent on their ongoing service to the company. This strategic move aims to retain key leadership during a critical time of change.
Learn more about RGNX stock on TipRanks’ Stock Analysis page.
